Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News EyePoint Inc EYPT

Healthcare Biotechnology
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated... see more

Current News (NDAQ:EYPT)

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire 7 hours ago

EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments

GlobeNewswire 12 days ago

EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU(TM) for the Treatment of Diabetic Macular Edema

GlobeNewswire March 2, 2026

EyePoint to Report Fourth Quarter and Full-Year 2025 Financial Results on March 4, 2026

GlobeNewswire February 25, 2026

EyePoint Announces Participation at Upcoming Investor Conferences

GlobeNewswire February 24, 2026

EyePoint Appoints Michael Campbell as Chief Commercial Officer

GlobeNewswire February 18, 2026

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire February 17, 2026

EyePoint to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

GlobeNewswire February 5, 2026

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire January 16, 2026
View More News ››

Opinion & Analysis (NDAQ:EYPT)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:EYPT)

I "SEE" nothing but $$$$$$$ Coming our way!

Here's to LOOKING up!!
PumperGuy - January 22, 2024

EYEPOINT PHARMACEUTICALS: A BOON FOR EYE DISEASE PATIENTS

$EYPT Excited to share an article about EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) - the Company develops and commercializes...
AviseAnalytics - January 5, 2024
View more Bullboard ››

Desert Gold Ventures Inc.

Desert Gold Ventures Inc.

Desert Gold Ventures Inc., an exploration stage company, engages in the acquisition, exploration, and development of mineral ...
View More »

Podcasts